ID | 64233 |
フルテキストURL | |
著者 |
Nishimura, Tomoka
Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Ichihara, Eiki
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Kaken ID
publons
Yokoyama, Toshihide
Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital
Inoue, Koji
Department of Respiratory Medicine, Ehime Prefectural Central Hospital
Tamura, Tomoki
Department of Respiratory Medicine, NHO Iwakuni Clinical Center
Sato, Ken
Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center
Oda, Naohiro
Department of Internal Medicine, Fukuyama City Hospital
Kano, Hirohisa
Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital
ORCID
Kishino, Daizo
Department of Respiratory Medicine, Japanese Red Cross Society Himeji Hospital
Kawai, Haruyuki
Department of Internal Medicine, Okayama Saiseikai General Hospital
Inoue, Masaaki
Department of Chest Surgery, Shimonoseki City Hospital
Ochi, Nobuaki
Department of General Internal Medicine 4, Kawasaki Medical School
Fujimoto, Nobukazu
Department of Respiratory Medicine, Okayama Rosai Hospital
Ichikawa, Hirohisa
Department of Respiratory Medicine, KKR Takamatsu Hospital
Ando, Chihiro
Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Hotta, Katsuyuki
Center for Innovative Clinical Medicine, Okayama University Hospital
Kaken ID
publons
researchmap
Maeda, Yoshinobu
Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Kaken ID
researchmap
Kiura, Katsuyuki
Department of Allergy and Respiratory Medicine, Okayama University Hospital
ORCID
Kaken ID
publons
researchmap
|
抄録 | Simple Summary Minimal data exists on pleural effusion (PE) for non-small cell lung cancer (NSCLC) patients undergoing combined ICI and chemotherapy. We retrospectively investigated how PE affects survival outcomes in patients with NSCLC undergoing this combined therapy. We identified 478 patients who underwent combined ICI therapy and chemotherapy; 357 patients did not have PE, and 121 patients did have PE. Patients with PE had significantly shorter progression-free survival and overall survival than those without PE. In addition, bevacizumab-containing regimens did not improve the survival outcomes for patients with PE. In conclusion, PE was associated with poor outcomes among patients with NSCLC undergoing combined ICI therapy and chemotherapy. Objectives: Combined immune checkpoint inhibitor (ICI) therapy and chemotherapy has become the standard treatment for advanced non-small-cell lung cancer (NSCLC). Pleural effusion (PE) is associated with poor outcomes among patients with NSCLC undergoing chemotherapy. However, minimal data exists on PE for patients undergoing combined ICI and chemotherapy. Therefore, we investigated how PE affects survival outcomes in patients with NSCLC undergoing this combined therapy. Methods: We identified patients with advanced NSCLC undergoing chemotherapy and ICI therapy from the Okayama Lung Cancer Study Group-Immune Chemotherapy Database (OLCSG-ICD) between December 2018 and December 2020; the OLCSG-ICD includes the clinical data of patients with advanced NSCLC from 13 institutions. Then, we analyzed the treatment outcomes based on the presence of PE. Results: We identified 478 patients who underwent combined ICI therapy and chemotherapy; 357 patients did not have PE, and 121 patients did have PE. Patients with PE had significantly shorter progression-free survival (PFS) and overall survival (OS) than those without PE (median PFS: 6.2 months versus 9.1 months; p < 0.001; median OS: 16.4 months versus 27.7 months; p < 0.001). The negative effect of PE differed based on the patient's programmed cell death-ligand 1 (PD-L1) expression status; with the effect being more evident in patients with high PD-L1 expression. In addition, PFS and OS did not differ between patients who did and did not undergo bevacizumab treatment; thus, bevacizumab-containing regimens did not improve the survival outcomes for patients with PE. Conclusion: PE is associated with poor outcomes among patients with NSCLC undergoing combined ICI therapy and chemotherapy.
|
キーワード | pleural effusion
non-small cell carcinoma
immune checkpoint inhibitors
|
発行日 | 2022-12-14
|
出版物タイトル |
Cancers
|
巻 | 14巻
|
号 | 24号
|
出版者 | MDPI
|
開始ページ | 6184
|
ISSN | 2072-6694
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2022 by the authors.
|
論文のバージョン | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.3390/cancers14246184
|
ライセンス | https://creativecommons.org/licenses/by/4.0/
|